Rhabdoid Tumour Predisposition Syndrome
RTPS
INI1
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1
Deletion/duplication analysis via MLPA; Sequencing
Blood; gDNA
Extracted DNA will not be accepted for the MLPA portion of this test.
- Blood: 5-10 mL in EDTA, 0.5 mL in EDTA (neonate);
- DNA-minimum 10 ug in 100 uL low TE (pH8.0)
Room Temperature
For details about specimen requirements, please refer to: Specimen Type and Requirements
DNA extracted at an external lab is not accepted for MLPA testing.
Special Instructions for Genome Diagnostics Samples
If sample shipment >48 hours, ship on ice.
Rhabdoid tumour predisposition syndrome 1 (RTPS-1) is a cancer syndrome that predisposes an individual to rhabdoid tumours. These tumours are referred to as atypical teratoid/rhabdoid tumours (AT/RT) when arising in the central nervous system, and as malignant rhabdoid tumours (MRTs) if found in other sites (i.e. renal, liver, lung, skin, heart). Most of these tumours are characterized by loss of function of the SMARCB1 gene. Germline mutations in SMARCB1 can predispose an individual to developing these tumours. Rhabdoid tumours are highly malignant and usually occur in children less than 2 years of age, and may present in multiple sites. Schwannomatosis is a genetic condition characterized by multiple schwannomas. Schwannomas can arise wherever Schwann cells occur, in the spinal cord and along peripheral and cranial nerves. The most common presentation of non-vestibular nerve schwannomas is painful lumps along the skin and/or neurological deficits.
See related information sheet: Rhabdoid tumour predisposition syndrome
Rhabdoid Tumour Predisposition Syndrome
Browse tests by laboratory
Customer Service
Toll Free: 1-855-381-3212
Local: 416-813-7200